EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer

Alex C Y Chen, Keely Y Ji, Cansu Yerinde, Nelson H Knudsen, Kevin Bi, Shumeng Hao, Vasyl Zhabotynsky, Daniela Martinez, Thomas J Carmona-LaSalle, Kazuhiro Taguchi, Katherine H Xu, Elizabeth M Seider und 10 weitere

Cell · 2026-10 · 189 (21) · 6738-6751.e7

DOI: 10.1016/j.cell.2026.07.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2026-10. Verfasst von Alex C Y Chen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms, Aging, Clustered Regularly Interspaced Short Palindromic Repeats. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Science Foundation, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune aging impairs T cell-mediated tumor control as well as cancer immunotherapy outcomes. The most important drivers of T cell dysfunction in aged tumors remain unknown. We performed single-cell CRISPR screens to identify Dusp5 and Zfp219 as key regulators of CD8+ T cell persistence and effector differentiation within aged tumors. Loss of Dusp5 increased extracellular signal-regulated kinase (ERK) phosphorylation and globally enhanced T cell proliferation. Conversely, Zfp219 deletion induced epigenetic reprogramming and increased expression of cytotoxic molecules, enhancing antitumor immunity specifically in aging. Levels of the human ortholog ZNF219 were higher within intratumoral CD8+ T cells from older cancer patients, which correlates with worse survival following immunotherapy. Zfp219 ablation synergized with immune checkpoint inhibitors to expand effector-like CD8+ T cells, leading to tumor clearance in aged mice. Our findings highlight Dusp5 and Zfp219 as critical drivers of age-related T cell dysfunction that can be targeted to rejuvenate antitumor immunity in older cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesNeoplasmsAgingClustered Regularly Interspaced Short Palindromic RepeatsAnimalsHumansMiceDual-Specificity PhosphatasesImmunotherapyMice, Inbred C57BLT-LymphocytesCRISPR-Cas SystemsCell Proliferation

Stichwörter der Autor:innen

T cellsantitumor immunitycancer immunology and immunotherapyimmune agingin vivo single-cell CRISPR screen

Substanzen

Dual-Specificity Phosphatases

Autor:innen und Institutionen

  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Center…
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA; Department of Pathology, Harvard Medical School, Bosto…
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Medicine, Harvard Medical School, Boston, MA, USA; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.

Förderung

  • NIAID NIH HHS
  • National Science Foundation
  • National Cancer Institute
  • Global Fund for Women
  • Burroughs Wellcome Fund
  • National Institutes of Health
  • V Foundation for Cancer Research
  • Melanoma Research Alliance

Zitieren

APA

Chen, A. C. Y., Ji, K. Y., Yerinde, C., Knudsen, N. H., Bi, K., Hao, S., Zhabotynsky, V., Martinez, D., Carmona-LaSalle, T. J., Taguchi, K., Xu, K. H., Seider, E. M., Schwartz, M. A., Zschummel, M., Nieman, L. T., Yates, K. B., Gazzaniga, F. S., Miller, B. C., Mempel, T. R., …, & Sen, D. R. (2026). CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer. Cell, 189(21), 6738-6751.e7. https://doi.org/10.1016/j.cell.2026.07.016

Vancouver

Chen ACY, Ji KY, Yerinde C, Knudsen NH, Bi K, Hao S, et al. CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer. Cell. 2026;189(21):6738-6751.e7. doi:10.1016/j.cell.2026.07.016

BibTeX
@article{Chen2026,
  author = {Chen, Alex C Y and Ji, Keely Y and Yerinde, Cansu and Knudsen, Nelson H and Bi, Kevin and Hao, Shumeng and Zhabotynsky, Vasyl and Martinez, Daniela and Carmona-LaSalle, Thomas J and Taguchi, Kazuhiro and Xu, Katherine H and Seider, Elizabeth M and Schwartz, Marc A and Zschummel, Maria and Nieman, Linda T and Yates, Kathleen B and Gazzaniga, Francesca S and Miller, Brian C and Mempel, Thorsten R and Manguso, Robert T and Hacohen, Nir and Sen, Debattama R},
  title = {CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {21},
  pages = {6738--6751.e7},
  doi = {10.1016/j.cell.2026.07.016}
}
Kostenlos starten →